GC Genome

GC Genome EBITDA per Share

The EBITDA per Share of GC Genome (340450.KQ) as of Oct 27, 2026 is 52.24 KRW. In the previous year, EBITDA per Share was -36.88 KRW — a change of -241.68% (higher).

EBITDA per Share

52.24KRW

YoY

-241.68%

Last updated:

EBITDA per Share of GC Genome is 2025 52.24 KRW. EBITDA per Share of GC Genome was 2024 -36.88 KRW. It decreases by -241.68% higher compared to the previous year.

The GC Genome EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
-113.62 KRW
Jan 1, 2023
21.50 KRW
Jan 1, 2024
-36.88 KRW
Jan 1, 2025
52.24 KRW
The GC Genome EBITDA per Share history
YEAREBITDA per ShareYoY
52.24KRW-241.68%
-36.88KRW-271.48%
21.50KRW-118.93%
-113.62KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GC Genome Stock analysis

What does GC Genome do? GC Genome Corp provides prenatal and newborn screening genetic testing services, cancer patient precision diagnosis genetic testing services, and precision diagnosis genetic testing for rare diseases. The company also offers health checkup test services. These services are sold to healthcare providers, hospitals, and clinics seeking advanced diagnostic solutions. The firm generates revenue through direct contracts with medical institutions for these specialized genetic testing packages. The company's core products include clinical genome analysis services tailored for specific medical scenarios. Prenatal and newborn screening targets expectant parents and pediatric care facilities, while cancer and rare disease diagnostics serve oncology and specialized medical departments. Health checkup tests are marketed to wellness centers and preventive care programs. GC Genome Corp's business model relies on recurring contracts with healthcare institutions for ongoing genetic testing needs. The firm's services are positioned as premium diagnostic tools for high-value medical applications, attracting clients focused on precision medicine and early disease detection. GC Genome is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GC Genome stock

EBITDA per Share of GC Genome is 52.24 KRW in 2025.

EBITDA per Share of GC Genome changed from -36.88 KRW to 52.24 KRW, representing a -241.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share GC Genome since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GC Genome

All Key Metrics — GC Genome